Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus trastuzumab for HER2-positive gastric/gastroesophageal junction cancer
ChiCTR2400088975Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and trastuzumab in HER2-positive gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate (ORR). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
disitamab vedotintrastuzumab
03
Conditions
HER2-positive gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400088975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088975.